Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK ...

Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, ...

Both ERAS-4001 and potential best-in-class pan-RAS molecular glue ERAS-0015 received IND clearance in May ahead of company guidance. Initial Phase 1 monotherapy data for both RAS- ...

Researchers led by Université de Montréal pathology and cell-biology professor Marc Therrien have identified major structural ...

Fusarium graminearum causes Fusarium head blight in cereals and stalk rot in maize, mainly affecting crops in the US, Canada, ...

The United Democratic Movement (UDM) will receive Ksh22,372,524, while the National Assembly speaker, Moses Wetang'ula's ...

Creative Biolabs recently updated its antibody chip platform, expanding product arrays for phosphorylation signaling and ...

As of the cut-off date of April 2, 2025, a total of 21 patients had been enrolled and received at least one dose of PAS-004 ...

Abstract:        Obesity, a growing global issue, has been closely associated with an increased risk of various cancers, especially breast cancer. El ...

A new review sheds light on the complex molecular mechanisms behind Angelman syndrome (AS), a rare neurogenetic disorder, and ...

Mackenzie Financial Corp acquired a new position in shares of Erasca, Inc. (NASDAQ:ERAS – Free Report) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange ...